Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome
- Demosthenes Bouros, M. Alexandrakis, +7 authors D. Kyriakou
- BMC pulmonary medicine
- 17 August 2004
BALF and serum levels of the studied cytokines on admission may provide valuable information for ARDS development in patients at risk, and outcome in patients either in ARDS or in at risk for AR DS. Expand
Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
- M. Koukourakis, George Patlakas, +5 authors Demosthenes Bouros
- Anticancer research
- 1 September 2007
Given the simplicity of HypoARC, the very low morbidity, and the high complete response and survival rates obtained, hypoARC regimens deserve further testing. Expand
Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer.
- George Patlakas, Demosthenes Bouros, Sofia Tsantekidou-Pozova, M. Koukourakis
- Anticancer research
- 1 March 2005
The efficacy of the regimen was as high as the one reported in gemcitabine/docetaxel studies, but the toxicity was remarkably lower, and amifostine may have contributed to the better tolerance profile observed. Expand
Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
- M. Koukourakis, C. Simopoulos, +6 authors C. Manolas
- Clinical cancer research : an official journal of…
- 15 August 2003
Although preliminary, 1000 mg of amifostine effectively protected against the lower, still more frequently administered doses of chemotherapy given once every 2 weeks. Expand
Application of microarray technology in pulmonary diseases
An overview of the application of microarray technology in research relevant to common lung diseases and some of the future perspectives are presented. Expand